Fox Run Management’s Soleno Therapeutics SLNO Stock Holding History

Fox Run Management’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,934	Closed	-$607K	–	1273
2026 Q1	$607K	Sell	19,934 -1,851	-8%	-$72.6K	0.11%	359
2025 Q4	$1.01M	Buy	21,785 +17,928	+465%	+$983K	0.16%	205
2025 Q3	$261K	Buy	+3,857	New	+$286K	0.04%	732

Fox Run Management's SLNO Position: Q2 2026 in Review

Fox Run Management sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 19,934 shares — an estimated $607K sold.

Fox Run Management first reported a position in SLNO in Q3 2025 and held it in 3 quarters. The position peaked at $1.01M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Fox Run Management reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Fox Run Management sold 19,934 Soleno Therapeutics shares in Q2 2026, an estimated $607K.
Fox Run Management first reported a position in Soleno Therapeutics in Q3 2025 and held it in 3 quarters.
Fox Run Management's Soleno Therapeutics position peaked at $1.01M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.